Glutamate receptors as a target for Alzheimer’s disease — are clinical results supporting the hope?
Several years after the introduction of cholinergic drugs in Alzheimer’s disease therapy, other approaches for symptomatic and also disease-modifying pharmacotherapy are progressing in their development. Among these, the NMD A antagonist memantine represents the most advanced and promising agent, gifted with many years of clinical experience in Germany. This paper provides an overview of both, the novel pharmacological background and recent clinical evidence in dementia. Memantine was recently recommended for central European approval.
KeywordsVascular Dementia Neurobiol Aging Severe Impairment Battery Memantine Treatment Memantine Group
Unable to display preview. Download preview PDF.
- Gortelmeyer R, Erbler H (1992) Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelfor-schung/Drug Res 42(7): 904–913Google Scholar
- Launer LJ, Hofman A (2000) Frequency and impact of neurologic diseases in the elderly of Europe: a collaborative study of population-based cohorts. Neurology 54[11 Suppl5]: 1–8Google Scholar
- Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR,Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A (2000) Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54[11 Suppl5]: S4–9PubMedGoogle Scholar
- Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F (2002) Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke (in press)Google Scholar
- Palmer AM, Gershon S (1990) Is the neuronal basis of Alzheimer’s disease cholinergic or glutamergic? FASEB J 4: 2745–2752Google Scholar
- Sahin K, Stoffler A, Furtuna P, Rosenwald D, Mobius HJ (2000) Dementia severity and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. Neurobiol Aging 21 (IS):S168Google Scholar
- Saxton J, McGonigle KL, Swihart AA, Boiler F (1993) The Severe Impairment Battery. The University of Pittsburgh of the Commonwealth System of Higher Education (eds) Thames Valley Test Company, Suffolk, pp 1–16Google Scholar
- van der Kam P, Mol F, Wimmers MFHC (1986) [Assessment scale for geriatric patients] Beordelingsschaal voor Oudere Patienten (BOP). Van Loghum Slaterus, The NetherlandsGoogle Scholar
- Wilcock G, Mobius HJ, Stoffler A, on behalf of the MMM 5000 Group (2002) A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). Int Clin Psychopharmacol (in press)Google Scholar